To the Editor On behalf of our coauthors, we write to report errors that occurred in the Original Investigation, “Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial,”1 that was published online March 20, 2019, and in the May print issue of JAMA Dermatology. This article reported the results of a trial in which 27 patients with mycosis fungoides (MF) were treated with oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks until complete response (CR). Eleven patients with CR were randomly assigned to receive psoralen–UV-A (PUVA) photochemotherapy maintenance for 9 months and 8 patients with CR were randomly assigned to no maintenance.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wolf P, Vieyra-Garcia P. Explanation of Additional Errors in Report of Trial of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment. JAMA Dermatol. 2019;155(10):1200–1201. doi:10.1001/jamadermatol.2019.2698
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.